Stay updated with breaking news from Evotec Bayer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
04.02.2022 Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets | Evotec SE | News | Nachricht | Mitteilung
Evotec SE: Bayer discontinues clinical development candidate eliapixant , Evotec regains the rights to all P2X3 assets Hamburg, Germany - Evotec SE announces today that the... | February 4, 2022
Investegate announcements from Evotec SE, Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets